189 related articles for article (PubMed ID: 33444606)
1. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
Briand F; Maupoint J; Brousseau E; Breyner N; Bouchet M; Costard C; Leste-Lasserre T; Petitjean M; Chen L; Chabrat A; Richard V; Burcelin R; Dubroca C; Sulpice T
Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
3. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
4. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death.
Briand F; Heymes C; Bonada L; Angles T; Charpentier J; Branchereau M; Brousseau E; Quinsat M; Fazilleau N; Burcelin R; Sulpice T
Clin Transl Sci; 2020 May; 13(3):529-538. PubMed ID: 31981449
[TBL] [Abstract][Full Text] [Related]
5. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
[No Abstract] [Full Text] [Related]
6. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
Baandrup Kristiansen MN; Veidal SS; Christoffersen C; Feigh M; Vrang N; Roth JD; Erickson M; Adorini L; Jelsing J
BMC Gastroenterol; 2019 Dec; 19(1):228. PubMed ID: 31883514
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
van den Hoek AM; Verschuren L; Caspers MPM; Worms N; Menke AL; Princen HMG
Sci Rep; 2021 Mar; 11(1):5050. PubMed ID: 33658534
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery.
Boeckmans J; Gatzios A; Heymans A; Rombaut M; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
Cells; 2022 Mar; 11(5):. PubMed ID: 35269515
[TBL] [Abstract][Full Text] [Related]
9. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice.
Tsai HC; Chang FP; Li TH; Liu CW; Huang CC; Huang SF; Yang YY; Lee KC; Hsieh YC; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC
Biomed Res Int; 2019; 2019():6740616. PubMed ID: 31321239
[TBL] [Abstract][Full Text] [Related]
10. Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet.
Svop Jensen V; Fledelius C; Max Wulff E; Lykkesfeldt J; Hvid H
Nutrients; 2021 Feb; 13(2):. PubMed ID: 33673227
[TBL] [Abstract][Full Text] [Related]
11. The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
Liu L; Liu C; Zhao M; Zhang Q; Lu Y; Liu P; Yang H; Yang J; Chen X; Yao Y
PLoS One; 2020; 15(12):e0243911. PubMed ID: 33326461
[TBL] [Abstract][Full Text] [Related]
12. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
[TBL] [Abstract][Full Text] [Related]
13. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
Roth JD; Veidal SS; Fensholdt LKD; Rigbolt KTG; Papazyan R; Nielsen JC; Feigh M; Vrang N; Young M; Jelsing J; Adorini L; Hansen HH
Sci Rep; 2019 Jun; 9(1):9046. PubMed ID: 31227742
[TBL] [Abstract][Full Text] [Related]
14. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
Gore E; Bigaeva E; Oldenburger A; Jansen YJM; Schuppan D; Boersema M; Rippmann JF; Broermann A; Olinga P
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G336-G351. PubMed ID: 31905025
[TBL] [Abstract][Full Text] [Related]
15. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.
Boeckmans J; Buyl K; Natale A; Vandenbempt V; Branson S; De Boe V; Rogiers V; De Kock J; Rodrigues RM; Vanhaecke T
Pharmacol Res; 2019 Jun; 144():377-389. PubMed ID: 31028903
[TBL] [Abstract][Full Text] [Related]
16. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
[TBL] [Abstract][Full Text] [Related]
17. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
[TBL] [Abstract][Full Text] [Related]
18. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis.
Mauer AS; Hirsova P; Maiers JL; Shah VH; Malhi H
Am J Physiol Gastrointest Liver Physiol; 2017 Mar; 312(3):G300-G313. PubMed ID: 28039158
[TBL] [Abstract][Full Text] [Related]
20. A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet.
Miyaoka Y; Jin D; Tashiro K; Masubuchi S; Ozeki M; Hirokawa F; Hayashi M; Takai S; Uchiyama K
Exp Anim; 2018 May; 67(2):239-247. PubMed ID: 29311502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
